Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use.

Published

Journal Article

INTRODUCTION: The Family Smoking Prevention and Tobacco Control Act authorized the FDA to reduce the nicotine content in cigarettes. Research is needed to guide proposed regulations, including evaluation of consequences to public health. This study evaluated how a reduced nicotine product standard might be moderated by and impact cannabis use. METHODS: Secondary analysis of a controlled clinical trial examining the effects of nicotine content in cigarettes in adult daily smokers. Linear regression assessed whether baseline cannabis use moderated behavioral, subjective, or physiological effects of smoking very low nicotine content (VLNC) versus normal nicotine content (NNC) cigarettes. Repeated measures analysis of associations between nicotine condition and prevalence and frequency of cannabis use was completed using generalized estimating equations (GEE). RESULTS: Cannabis use did not moderate most of the following effects of VLNC cigarettes: Among cannabis users and non-users, smokers randomized to VLNC cigarettes reported lower nicotine dependence, cigarettes per day, biomarkers of nicotine exposure, and craving compared to smokers randomized to NNC cigarettes. Non-cannabis using smokers randomized to VLNC cigarettes also reported lower smoking dependence motives and had lower tobacco-specific nitrosamine exposure and total puff volume versus smokers randomized to NNC cigarettes. For cannabis users, smokers randomized to VLNC cigarettes reported decreased positive affect. VLNC cigarette use did not impact the prevalence or frequency of cannabis use. DISCUSSION: Findings provide evidence that nicotine reduction in cigarettes could have beneficial effects on cigarette smoking regardless of cannabis use. Results suggest that transitioning to VLNC cigarettes is unlikely to alter current rates of cannabis use.

Full Text

Duke Authors

Cited Authors

  • Pacek, LR; Vandrey, R; Dermody, SS; Denlinger-Apte, RL; Lemieux, A; Tidey, JW; McClernon, FJ; Bangdiwala, AS; Drobes, DJ; al'Absi, M; Strasser, AA; Koopmeiners, JS; Hatsukami, DK; Donny, EC

Published Date

  • October 1, 2016

Published In

Volume / Issue

  • 167 /

Start / End Page

  • 228 - 232

PubMed ID

  • 27590743

Pubmed Central ID

  • 27590743

Electronic International Standard Serial Number (EISSN)

  • 1879-0046

Digital Object Identifier (DOI)

  • 10.1016/j.drugalcdep.2016.08.620

Language

  • eng

Conference Location

  • Ireland